Literature DB >> 11384227

Basic amino acid residues in the V3 loop of simian immunodeficiency virus envelope alter viral coreceptor tropism and infectivity but do not allow efficient utilization of CXCR4 as entry cofactor.

S Meister1, C Otto, A Papkalla, M Krumbiegel, S Pöhlmann, F Kirchhoff.   

Abstract

In contrast to human immunodeficiency viruses type 1 and type 2 (HIV-1 and HIV-2, respectively), simian immunodeficiency virus (SIVmac) rarely uses CXCR4 (X4) for efficient entry into target cells. Basic amino acid residues in the V3 loop of HIV Env allow efficient coreceptor utilization of X4. Therefore, we investigated if similar changes in the SIVmac Env protein also mediate a coreceptor switch from CCR5 (R5) to X4. Functional analysis revealed that none of eight SIVmac variants, containing V3 regions with an overall charge between +4 and +10, efficiently utilized X4 as entry cofactor. Nonetheless, these alterations had differential effects on SIV coreceptor tropism and on Env expression levels. A single amino acid substitution of L328R, located near the tip of the V3 loop, resulted in grossly reduced Env expression levels and impaired viral infectivity. Notably, additional basic residues restored efficient Env expression and virion incorporation but not infectivity. In comparison to the L328R mutation, changes of P334K and D337K had little disruptive effects on SIVmac entry and replication. Interestingly, mutation of L320K and P321R disrupted coreceptor usage of GPR15 but not R5. These changes also impaired SIVmac replication in peripheral blood mononuclear cells (PBMC) derived from a Delta32/Delta32 donor but not in R5-expressing human or simian PBMC. Our results show that positively charged amino acid residues in the V3 loop affect SIVmac coreceptor tropism and infectivity but do not allow efficient utilization of X4. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11384227     DOI: 10.1006/viro.2001.0852

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  5 in total

1.  Gene silencing of HIV chemokine receptors using ribozymes and single-stranded antisense RNA.

Authors:  Amer Qureshi; Richard Zheng; Terry Parlett; Xiaoju Shi; Priyadhashini Balaraman; Sihem Cheloufi; Brendan Murphy; Christine Guntermann; Peter Eagles
Journal:  Biochem J       Date:  2006-03-01       Impact factor: 3.857

2.  Impact of viral factors on very early in vivo replication profiles in simian immunodeficiency virus SIVagm-infected African green monkeys.

Authors:  Ivona Pandrea; Christopher Kornfeld; Mickael J-Y Ploquin; Cristian Apetrei; Abdourahmane Faye; Pierre Rouquet; Pierre Roques; François Simon; Françoise Barré-Sinoussi; Michaela C Müller-Trutwin; Ousmane M Diop
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

3.  Derivation and characterization of a simian immunodeficiency virus SIVmac239 variant with tropism for CXCR4.

Authors:  Gregory Q Del Prete; Beth Haggarty; George J Leslie; Andrea P O Jordan; Josephine Romano; Nathaniel Wang; Jianbin Wang; Michael C Holmes; David C Montefiori; James A Hoxie
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

4.  Amino acid 324 in the simian immunodeficiency virus SIVmac V3 loop can confer CD4 independence and modulate the interaction with CCR5 and alternative coreceptors.

Authors:  Stefan Pöhlmann; Carl Davis; Silke Meister; George J Leslie; Claas Otto; Jacqueline D Reeves; Bridget A Puffer; Armin Papkalla; Mandy Krumbiegel; Andrea Marzi; Steffen Lorenz; Jan Münch; Robert W Doms; Frank Kirchhoff
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

5.  Engineered CD4- and CXCR4-using simian immunodeficiency virus from African green monkeys is neutralization sensitive and replicates in nonstimulated lymphocytes.

Authors:  Renate R König; Egbert Flory; Stefanie Steidl; Jeanette Neumann; Cheick Coulibaly; Edgar Holznagel; Silke Holzammer; Stephen Norley; Klaus Cichutek
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.